Loading...
NeuroSense Therapeutics Ltd.
NRSN•NASDAQ
HealthcareBiotechnology
$1.79
$0.07(4.07%)
NeuroSense Therapeutics Ltd. (NRSN) Stock Overview
Explore NeuroSense Therapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for NRSNStats details for NRSN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NRSNAnalyst Recommendations details for NRSN are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
CEO
Mr. Alon Ben-Noon
Employees
17
Headquarters
Building B, Herzliya
Founded
2021